Summary
71.42 0.18(0.25%)07/03/2024
Bio-Techne Corp (TECH)
Bio-Techne Corp (TECH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.28 | -0.89 | -8.22 | 5.25 | -0.96 | -11.98 | -66.62 | 19,094.54 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 71.42 | |
| Open | 71.87 | |
| High | 72.69 | |
| Low | 71.42 | |
| Volume | 402,923 | |
| Change | 0.20 | |
| Change % | 0.28 | |
| Avg Volume (20 Days) | 732,715 | |
| Volume/Avg Volume (20 Days) Ratio | 0.55 | |
| 52 Week Range | 51.80 - 89.91 | |
| Price vs 52 Week High | -20.57% | |
| Price vs 52 Week Low | 37.88% | |
| Range | -0.63 | |
| Gap Up/Down | -0.48 | |
Fundamentals | ||
| Market Capitalization (Mln) | 11,259 | |
| EBIDTA | 323,364,992 | |
| PE Ratio | 45.1799 | |
| PEG Ratio | 1.1476 | |
| WallStreet Target Price | 80.55 | |
| Book Value | 12.4950 | |
| Earnings Per Share | 1.3900 | |
| EPS Estimate Current Quarter | 0.4100 | |
| EPS Estimate Next Quarter | 0.4900 | |
| EPS Estimate Current Year | 1.7700 | |
| EPS Estimate Next Year | 2.0400 | |
| Diluted EPS (TTM) | 1.3900 | |
| Revenues | ||
| Profit Marging | 0.1958 | |
| Operating Marging (TTM) | 0.1839 | |
| Return on asset (TTM) | 0.0632 | |
| Return on equity (TTM) | 0.1183 | |
| Revenue TTM | 1,144,999,040 | |
| Revenue per share TTM | 7.2630 | |
| Quarterly Revenue Growth (YOY) | 0.0040 | |
| Quarterly Earnings Growth (YOY) | -0.4520 | |
| Gross Profit (TTM) | 770,215,000 | |
| Dividends | ||
| Dividend Share | 0.3200 | |
| Dividend Yield | 0.0051 | |
| Valuations | ||
| Trailing PE | 45.1799 | |
| Forward PE | 33.6700 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.3420 | |
| Revenue Enterprise Value | 9.5279 | |
| EBITDA Enterprise Value | 29.0156 | |
| Shares | ||
| Shares Outstanding | 157,192,000 | |
| Shares Float | 155,394,984 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 0.97 | |
| Institutions (%) | 100.52 | |
06/12 09:02 EST - prnewswire.com
CYBER ENVIRO-TECH ENTERS INTO A MEMORANDUM OF UNDERSTANDING TO ACQUIRE A SALT WATER DISPOSAL FACILITY IN THE PERMIAN BASIN
SCOTTSDALE, Ariz. , June 12, 2024 /PRNewswire/ -- (OTC Pink: CETI), Cyber Enviro-Tech, Inc. an international eco-conscious remediation company, is pleased to announce the signing of a Memorandum of Understanding to acquire a Salt Water Disposal (SWD) facility in the Permian Basin of West Texas.
CYBER ENVIRO-TECH ENTERS INTO A MEMORANDUM OF UNDERSTANDING TO ACQUIRE A SALT WATER DISPOSAL FACILITY IN THE PERMIAN BASIN
SCOTTSDALE, Ariz. , June 12, 2024 /PRNewswire/ -- (OTC Pink: CETI), Cyber Enviro-Tech, Inc. an international eco-conscious remediation company, is pleased to announce the signing of a Memorandum of Understanding to acquire a Salt Water Disposal (SWD) facility in the Permian Basin of West Texas.
06/06 09:02 EST - prnewswire.com
CYBER ENVIRO-TECH, INC ANNOUNCES BREAKTHROUGH WATER TREATMENT FOR NITRATES, PHOSPHATES, CYANIDES AND INSECTICIDES
SCOTTSDALE, Ariz. , June 6, 2024 /PRNewswire/ -- (OTCQB: CETI), CETI has unveiled its technological breakthrough for removing insecticides, nitrates, phosphates, and cyanide from heavily contaminated agricultural, industrial and mining wastewater.
CYBER ENVIRO-TECH, INC ANNOUNCES BREAKTHROUGH WATER TREATMENT FOR NITRATES, PHOSPHATES, CYANIDES AND INSECTICIDES
SCOTTSDALE, Ariz. , June 6, 2024 /PRNewswire/ -- (OTCQB: CETI), CETI has unveiled its technological breakthrough for removing insecticides, nitrates, phosphates, and cyanide from heavily contaminated agricultural, industrial and mining wastewater.
05/31 07:00 EST - prnewswire.com
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
MINNEAPOLIS , May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: William Blair 44th Annual Growth Conference June 4, 2024 9:20 AM CDT Jefferies Global Healthcare Conference June 6, 2024 9:30 AM EDT Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
MINNEAPOLIS , May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: William Blair 44th Annual Growth Conference June 4, 2024 9:20 AM CDT Jefferies Global Healthcare Conference June 6, 2024 9:30 AM EDT Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
05/30 07:00 EST - prnewswire.com
BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE
MINNEAPOLIS, May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, taking place June 2 nd-6th in Anaheim, California. The MauriceFlex system is Bio-Techne's latest imaged capillary isoelectric focusing (icIEF) solution, which enables icIEF-based fractionation in addition to routine icIEF and capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) assays.
BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE
MINNEAPOLIS, May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, taking place June 2 nd-6th in Anaheim, California. The MauriceFlex system is Bio-Techne's latest imaged capillary isoelectric focusing (icIEF) solution, which enables icIEF-based fractionation in addition to routine icIEF and capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) assays.
05/29 07:00 EST - prnewswire.com
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing
ST. PAUL, Minn. , May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene therapies (CGT).
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing
ST. PAUL, Minn. , May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene therapies (CGT).
05/23 07:00 EST - prnewswire.com
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
MINNEAPOLIS , May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 8:40 a.m. CDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
MINNEAPOLIS , May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 8:40 a.m. CDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
05/22 07:00 EST - prnewswire.com
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY
MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The two companies began the collaboration in 2020 to support Regulus' biomarker analysis for the clinical development of anti-miR-17 therapies for ADPKD treatment.
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY
MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The two companies began the collaboration in 2020 to support Regulus' biomarker analysis for the clinical development of anti-miR-17 therapies for ADPKD treatment.
05/21 15:00 EST - businesswire.com
Court Revokes Two Advanced Cell Diagnostics Patents, Dismisses Infringement Claims Against Molecular Instruments and Orders Advanced Cell Diagnostics to Make Payment of £1.35 Million to Molecular Instruments
LOS ANGELES--(BUSINESS WIRE)-- #Biotech--Molecular Instruments announced that UK Patents Court orders Advanced Cell Diagnostics to make £1.35 million costs payment to Molecular Instruments.
Court Revokes Two Advanced Cell Diagnostics Patents, Dismisses Infringement Claims Against Molecular Instruments and Orders Advanced Cell Diagnostics to Make Payment of £1.35 Million to Molecular Instruments
LOS ANGELES--(BUSINESS WIRE)-- #Biotech--Molecular Instruments announced that UK Patents Court orders Advanced Cell Diagnostics to make £1.35 million costs payment to Molecular Instruments.
05/20 13:34 EST - investorplace.com
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.
05/08 11:56 EST - zacks.com
5 Stocks at the Forefront of S&P 500 ETF's Latest Rally
The S&P 500 is up for the fourth consecutive session. While many stocks have powered the ETF, we have highlighted five that have led the way higher.
5 Stocks at the Forefront of S&P 500 ETF's Latest Rally
The S&P 500 is up for the fourth consecutive session. While many stocks have powered the ETF, we have highlighted five that have led the way higher.
05/08 07:00 EST - prnewswire.com
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024
MINNEAPOLIS , May 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 14, 2024, at 2:20 p.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024
MINNEAPOLIS , May 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 14, 2024, at 2:20 p.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
05/07 07:00 EST - prnewswire.com
BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)
MINNEAPOLIS , May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland. Bio-Techne's booth (#1627) will feature our market-leading portfolio of high-quality life science research use only (RUO) and Good Manufacturing Practice (GMP) reagents, immunoassays, automated proteomic analytical instruments, and multi-omics solutions for accelerating cell and gene therapy development and manufacturing.
BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)
MINNEAPOLIS , May 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of cell and gene therapy workflow solutions at the upcoming annual meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland. Bio-Techne's booth (#1627) will feature our market-leading portfolio of high-quality life science research use only (RUO) and Good Manufacturing Practice (GMP) reagents, immunoassays, automated proteomic analytical instruments, and multi-omics solutions for accelerating cell and gene therapy development and manufacturing.
05/01 12:41 EST - zacks.com
HRMY or TECH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now?
HRMY or TECH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now?
05/01 10:35 EST - zacks.com
Techne (TECH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Techne (TECH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/01 08:41 EST - zacks.com
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Techne (TECH) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.53 per share a year ago.
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Techne (TECH) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.53 per share a year ago.
05/01 07:35 EST - reuters.com
Bio-Techne beats third-quarter estimates on improving demand for biotech products
Bio-Techne on Wednesday beat third-quarter profit and revenue estimates, helped by better-than-expected demand for its cell and gene therapy products and testing and diagnostic devices.
Bio-Techne beats third-quarter estimates on improving demand for biotech products
Bio-Techne on Wednesday beat third-quarter profit and revenue estimates, helped by better-than-expected demand for its cell and gene therapy products and testing and diagnostic devices.
05/01 06:30 EST - prnewswire.com
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS
MINNEAPOLIS , May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights Third quarter organic revenue increased by 2% (3% reported) to $303.4 million.
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS
MINNEAPOLIS , May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights Third quarter organic revenue increased by 2% (3% reported) to $303.4 million.
05/01 06:30 EST - prnewswire.com
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS , May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2024. The quarterly dividend will be payable May 24, 2024, to all common shareholders of record on May 13, 2024.
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS , May 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2024. The quarterly dividend will be payable May 24, 2024, to all common shareholders of record on May 13, 2024.
04/30 07:00 EST - prnewswire.com
BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
MINNEAPOLIS , April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee.
BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
MINNEAPOLIS , April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee.
04/29 07:00 EST - prnewswire.com
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC
MINNEAPOLIS , April 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers. Effective May 1, 2024, Bio-Techne will enter into a strategic distribution agreement with Thermo Fisher Scientific, a leading provider of laboratory products and services, in Europe.
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC
MINNEAPOLIS , April 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities is pleased to announce a significant milestone in its commitment to providing cutting-edge solutions to its customers. Effective May 1, 2024, Bio-Techne will enter into a strategic distribution agreement with Thermo Fisher Scientific, a leading provider of laboratory products and services, in Europe.